Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sutro Biopharma ( (STRO) ) has provided an update.
On February 9, 2026, Sutro Biopharma entered an underwriting agreement with Leerink Partners and TD Securities to sell 7,868,383 shares of common stock at $13.98 per share, a public offering expected to generate about $110 million in gross proceeds and close on February 11, 2026, subject to customary conditions. Combined with existing cash, cash equivalents and marketable securities as of January 1, 2026, the raise will bring Sutro’s capital resources to roughly $251.4 million, extending its funding runway into the second quarter of 2028 and supporting research, clinical development, manufacturing scale-up and other general corporate uses as the company advances its ADC pipeline.
On February 10, 2026, Sutro plans to release an updated corporate presentation highlighting its proprietary ADC platform and differentiated pipeline of single- and dual-payload candidates, including STRO-004, STRO-006 and PTK7-targeting STRO-227, which are being developed for large oncology markets with significant unmet need. The presentation underscores Sutro’s claim to be at the forefront of next-generation ADCs, emphasizing enhanced exposure, safety and efficacy profiles in preclinical models and outlining a goal of bringing three investigational new drug applications in three years, reinforcing its positioning as a well-capitalized contender in the competitive ADC space.
The most recent analyst rating on (STRO) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.
Spark’s Take on STRO Stock
According to Spark, TipRanks’ AI Analyst, STRO is a Neutral.
The score is held back primarily by weak financial fundamentals—large losses, negative cash flow, and negative equity—despite strong revenue growth and margins. Technical momentum is constructive and provides support, while valuation remains constrained by unprofitability. The Nasdaq compliance update is a modest positive but secondary to the underlying financial risks.
To see Spark’s full report on STRO stock, click here.
More about Sutro Biopharma
Sutro Biopharma, Inc. is a biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for oncology, using a proprietary cell-free protein synthesis platform to engineer site-specific conjugation, dual- and single-payload designs, and improved pharmacokinetics. Its pipeline includes candidates such as STRO-004, STRO-006 and STRO-227, targeting complex tumor-associated antigens across large cancer indications.
Average Trading Volume: 112,200
Technical Sentiment Signal: Hold
Current Market Cap: $132.2M
For an in-depth examination of STRO stock, go to TipRanks’ Overview page.